Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
AAAS Promotion

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Originally published in Science Express on 26 April 2007
Science 18 May 2007:
Vol. 316. no. 5827, pp. 1039 - 1043
DOI: 10.1126/science.1141478
Prev | Table of Contents | Next

Reports

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman,1,2,3 Kreshnik Zejnullahu,4,5 Tetsuya Mitsudomi,6 Youngchul Song,2,3 Courtney Hyland,7 Joon Oh Park,4,5 Neal Lindeman,7 Christopher-Michael Gale,3 Xiaojun Zhao,5 James Christensen,8 Takayuki Kosaka,6 Alison J. Holmes,4,5 Andrew M. Rogers,5 Federico Cappuzzo,9 Tony Mok,10 Charles Lee,7 Bruce E. Johnson,4,5 Lewis C. Cantley,2,3 Pasi A. Jänne4,5*

The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.

1 Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
2 Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
3 Department of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
4 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
6 Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
7 Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
8 Pfizer Global Research and Development, Department of Research Pharmacology, La Jolla Laboratories, La Jolla, CA 92121, USA.
9 Istituto Clinico Humanitas, Department on Hematology-Oncology, Rozzano 20089, Italy.
10 Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.

* To whom correspondence should be addressed. E-mail: pjanne{at}partners.org

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Case 23-2008 -- A 26-Year-Old Man with Back Pain and a Mass in the Lung.
L. V. Sequist, J. E. Settleman, J. B. Ackman, and A. J. Iafrate (2008)
N. Engl. J. Med. 359, 405-414
   Full Text »    PDF »
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, et al. (2008)
N. Engl. J. Med. 359, 366-377
   Abstract »    Full Text »    PDF »
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
D. H. Lee, S.-W. Kim, C. Suh, D. H. Yoon, E. J. Yi, and J.-S. Lee (2008)
Ann. Onc.
   Abstract »    Full Text »    PDF »
Erlotinib in a Patient With Acute Myelogenous Leukemia and Concomitant Non-Small-Cell Lung Cancer.
V. Pitini, C. Arrigo, and G. Altavilla (2008)
J. Clin. Oncol. 26, 3645-3646
   Full Text »    PDF »
Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance.
T. Shimamura, D. Li, H. Ji, H. J. Haringsma, E. Liniker, C. L. Borgman, A. M. Lowell, Y. Minami, K. McNamara, S. A. Perera, et al. (2008)
Cancer Res. 68, 5827-5838
   Abstract »    Full Text »    PDF »
Class 1A PI3K regulates vessel integrity during development and tumorigenesis.
T. L. Yuan, H. S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J. V. Frangioni, and L. C. Cantley (2008)
PNAS 105, 9739-9744
   Abstract »    Full Text »    PDF »
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
L. P. Stabile, M. E. Rothstein, P. Keohavong, J. Jin, J. Yin, S. R. Land, S. Dacic, T. M. Luong, K. J. Kim, A. M. Dulak, et al. (2008)
Mol. Cancer Ther. 7, 1913-1922
   Abstract »    Full Text »    PDF »
MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2).
S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi (2008)
J. Biol. Chem. 283, 18158-18166
   Abstract »    Full Text »    PDF »
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma.
C. Montagut, S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al. (2008)
Cancer Res. 68, 4853-4861
   Abstract »    Full Text »    PDF »
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non-Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy.
C.-H. Yang, C.-J. Yu, J.-Y. Shih, Y.-C. Chang, F.-C. Hu, M.-C. Tsai, K.-Y. Chen, Z.-Z. Lin, C.-J. Huang, C.-T. Shun, et al. (2008)
J. Clin. Oncol. 26, 2745-2753
   Abstract »    Full Text »    PDF »
Neuregulins and Cancer.
J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella (2008)
Clin. Cancer Res. 14, 3237-3241
   Abstract »    Full Text »    PDF »
First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.
L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. (2008)
J. Clin. Oncol. 26, 2442-2449
   Abstract »    Full Text »    PDF »
Molecular Selection of Patients for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Inhibitors: Not Quite Ready for Prime Time.
F. A. Shepherd (2008)
J. Clin. Oncol. 26, 2426-2427
   Full Text »    PDF »
Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells.
J. N. Contessa, M. S. Bhojani, H. H. Freeze, A. Rehemtulla, and T. S. Lawrence (2008)
Cancer Res. 68, 3803-3809
   Abstract »    Full Text »    PDF »
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
J. A. Engelman and P. A. Janne (2008)
Clin. Cancer Res. 14, 2895-2899
   Abstract »    Full Text »    PDF »
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. (2008)
Ann. Onc.
   Abstract »    Full Text »    PDF »
Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells.
K. L. Mueller, L. A. Hunter, S. P. Ethier, and J. L. Boerner (2008)
Cancer Res. 68, 3314-3322
   Abstract »    Full Text »    PDF »
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation.
T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al. (2008)
Clin. Cancer Res. 14, 2465-2475
   Abstract »    Full Text »    PDF »
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer.
A. Kumar, E. T. Petri, B. Halmos, and T. J. Boggon (2008)
J. Clin. Oncol. 26, 1742-1751
   Abstract »    Full Text »    PDF »
FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival.
K. Kunii, L. Davis, J. Gorenstein, H. Hatch, M. Yashiro, A. Di Bacco, C. Elbi, and B. Lutterbach (2008)
Cancer Res. 68, 2340-2348
   Abstract »    Full Text »    PDF »
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
N. Godin-Heymann, L. Ulkus, B. W. Brannigan, U. McDermott, J. Lamb, S. Maheswaran, J. Settleman, and D. A. Haber (2008)
Mol. Cancer Ther. 7, 874-879
   Abstract »    Full Text »    PDF »
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
Y. Yang, M. Wislez, N. Fujimoto, L. Prudkin, J. G. Izzo, F. Uno, L. Ji, A. E. Hanna, R. R. Langley, D. Liu, et al. (2008)
Mol. Cancer Ther. 7, 952-960
   Abstract »    Full Text »    PDF »
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors.
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al. (2008)
Clin. Cancer Res. 14, 2220-2226
   Abstract »    Full Text »    PDF »
EGFR Antagonists in Cancer Treatment.
F. Ciardiello and G. Tortora (2008)
N. Engl. J. Med. 358, 1160-1174
   Full Text »    PDF »
Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations.
D. B. Costa, S. T. Schumer, D. G. Tenen, and S. Kobayashi (2008)
J. Clin. Oncol. 26, 1182-1184
   Full Text »    PDF »
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells.
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney (2008)
Cancer Res. 68, 1471-1477
   Abstract »    Full Text »    PDF »
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
H.-P. Kim, S.-W. Han, S.-H. Kim, S.-A. Im, D.-Y. Oh, Y.-J. Bang, and T.-Y. Kim (2008)
Mol. Cancer Ther. 7, 607-615
   Abstract »    Full Text »    PDF »
Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better.
T. Fojo (2008)
Oncologist 13, 277-283
   Full Text »    PDF »
Directional and quantitative phosphorylation networks.
C. Jorgensen and R. Linding (2008)
Brief Funct Genomic Proteomic
   Abstract »    Full Text »    PDF »
Signal Strength Dictates Phosphoinositide 3-Kinase Contribution to Ras/Extracellular Signal-Regulated Kinase 1 and 2 Activation via Differential Gab1/Shp2 Recruitment: Consequences for Resistance to Epidermal Growth Factor Receptor Inhibition.
C. Sampaio, M. Dance, A. Montagner, T. Edouard, N. Malet, B. Perret, A. Yart, J.-P. Salles, and P. Raynal (2008)
Mol. Cell. Biol. 28, 587-600
   Abstract »    Full Text »    PDF »
Signaling networks assembled by oncogenic EGFR and c-Met.
A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, et al. (2008)
PNAS 105, 692-697
   Abstract »    Full Text »    PDF »
Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor.
T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra (2008)
Mol. Cancer Res. 6, 139-150
   Abstract »    Full Text »    PDF »
Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling.
Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock (2008)
Am. J. Respir. Cell Mol. Biol. 38, 95-104
   Abstract »    Full Text »    PDF »
Emerging Therapies for Non-small Cell Lung Cancer.
P. A. Bunn Jr., E. B. Haura, and J. V. Heymach (2008)
ASCO Educational Book 2008, e5-e14
   Abstract »    Full Text »    PDF »
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
J. Bean, C. Brennan, J.-Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, et al. (2007)
PNAS 104, 20932-20937
   Abstract »    Full Text »    PDF »
Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion.
J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K.-K. Wong, and A. Letai (2007)
Cancer Res. 67, 11867-11875
   Abstract »    Full Text »    PDF »
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib.
J. A. Engelman, K. Zejnullahu, C.-M. Gale, E. Lifshits, A. J. Gonzales, T. Shimamura, F. Zhao, P. W. Vincent, G. N. Naumov, J. E. Bradner, et al. (2007)
Cancer Res. 67, 11924-11932
   Abstract »    Full Text »    PDF »
Oncogene addiction: setting the stage for molecularly targeted cancer therapy.
S. V. Sharma and J. Settleman (2007)
Genes & Dev. 21, 3214-3231
   Abstract »    Full Text »    PDF »
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
U. McDermott, S. V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, D. Lee, et al. (2007)
PNAS 104, 19936-19941
   Abstract »    Full Text »    PDF »
Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies.
Z. Yu, T. J. Boggon, S. Kobayashi, C. Jin, P. C. Ma, A. Dowlati, J. A. Kern, D. G. Tenen, and B. Halmos (2007)
Cancer Res. 67, 10417-10427
   Abstract »    Full Text »    PDF »
Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells Is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib.
P. Timpson, A. S. Wilson, G. M. Lehrbach, R. L. Sutherland, E. A. Musgrove, and R. J. Daly (2007)
Cancer Res. 67, 9304-9314
   Abstract »    Full Text »    PDF »
Targeted Agents: The Rules of Combination.
E. L. Kwak, J. W. Clark, and B. Chabner (2007)
Clin. Cancer Res. 13, 5232-5237
   Abstract »    Full Text »    PDF »
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non Small Cell Lung Cancer Cell Line.
A. Ogino, H. Kitao, S. Hirano, A. Uchida, M. Ishiai, T. Kozuki, N. Takigawa, M. Takata, K. Kiura, and M. Tanimoto (2007)
Cancer Res. 67, 7807-7814
   Abstract »    Full Text »    PDF »
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, and F. M. White (2007)
PNAS 104, 12867-12872
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)